Today's news release from Helix follows. For more information, please contact me by phone, fax, or e-mail as listed below...
TSE & VSE: "HBP"
APRIL 29, 1997
HELIX BIOPHARMA NEWS RELEASE
215 - 7080 RIVER ROAD
RICHMOND, B.C.
CANADA V6X 1X5
PHONE (604) 270-7468
FAX (604) 270-8208
TOLL FREE 1-800-563-4363
HELIX BIOPHARMA CORP. ANNOUNCES RESEARCH AND DEVELOPMENT AGREEMENT WITH PHARMADERM LABORATORIES LTD.
Development of Unique Drug Delivery Systems Underway
(RICHMOND, B.C.) - Helix BioPharma Corp. (TSE: HPB) today announced the completion of a series of agreements with Saskatoon-based PharmaDerm Laboratories Ltd. ("PharmaDerm") centered on a Research and Development arrangement for the continued development of PharmaDerm's most advanced pharmaceutical products. The agreements also provide Helix with world-wide manufacturing and marketing rights to PharmaDerm's most advanced products, which utilize its proprietary Dermal Drug Delivery Systems.
PharmaDerm's Dermal Drug Delivery Systems have the ability to deliver pharmaceuticals topically (on the skin surface), intradermally (into various layers of the skin), or transdermally (through the skin). Of special interest is the ability of the Dermal Drug Delivery Systems to deliver drug molecules of varying sizes, including proteins.
"The ability of PharmaDerm's Dermal Drug Delivery Systems to deliver pharmaceuticals directly to the required target site presents great potential therapeutic advantages," said Dr. Terrance Owen, President of Helix BioPharma Corp. "In addition, these delivery systems should dramatically reduce the side effects of certain compounds when compared to existing oral and injection routes of administration."
Helix will invest $650,000 to develop PharmaDerm's products, and will have the right to purchase up to 49% of PharmaDerm common shares for a nominal sum. Currently, PharmaDerm has filed patents for the Dermal Drug Delivery Systems in Europe, the United States, and other countries.
Dr. Marianna Foldvari, President of PharmaDerm Laboratories Ltd., said, "We're delighted to be working in partnership with an innovative biopharmaceutical company like Helix BioPharma. Our Dermal Drug Delivery Systems have extremely promising applications for the superior delivery of drugs. We look forward to the ongoing development of this technology and bringing products to markets in the near future."
The foregoing transactions are subject to regulatory approval.
Helix BioPharma Corp. is a growing health-care company focused on the development and commercialization of pharmaceuticals. Headquartered in Richmond, B.C., the Company has offices across Canada and internationally in Ireland, and is publicly-traded on the Toronto Stock Exchange.
- 30-
Investor Contact:
Jason Van Bergen, Investor Relations
Helix BioPharma Corp.
Tel: (604) 270-7468
Fax: (604) 270-8208
E-mail: invrelations@helixbiopharma.ca
Web-Site: helixbio.com
Media Contact:
Sarah Temple
Barr & Wilcox Group
Tel: (604) 488-1100
Fax: (604) 488-1122
E-mail: bwgroup@axionet.com
Web-Site: newshook.com |
